



## Clene to Present at Upcoming September Investor Conferences

August 30, 2022

SALT LAKE CITY, Aug. 30, 2022 (GLOBE NEWSWIRE) -- [Clene Inc.](#) (NASDAQ: CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that it will participate in the following investor conferences in September:

### **Citi's 17<sup>th</sup> Annual BioPharma Conference**

Date: September 8, 2022

Location: Four Seasons Hotel, Boston, MA

Format: 1x1 meetings

### **H.C. Wainwright 24<sup>th</sup> Annual Global Investment Conference**

Dates: September 12-13, 2022

Location: Lotte New York Palace Hotel, New York, NY

Date, Time and Location of Presentation: September 13, 2022, at 12:00 ET (Kennedy I)

Format: Corporate Presentation and 1x1 meetings

### **About CNM-Au8®**

CNM-Au8 is Clene's lead asset in mid- and late-stage clinical development for the treatment of multiple sclerosis and amyotrophic lateral sclerosis. An oral suspension of gold nanocrystals, CNM-Au8 was developed to restore neuronal health and function by increasing energy production and utilization. The catalytically active nanocrystals of CNM-Au8 drive critical cellular energy producing reactions that enable neuroprotection and remyelination by increasing neuronal and glial resilience to disease-relevant stressors. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc.

### **About Clene**

Clene is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease by targeting energetic failure, an underlying cause of many neurological diseases. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit [www.clene.com](http://www.clene.com) or follow us on [Twitter](#), [LinkedIn](#) and [Facebook](#).

### **Media Contact**

Ignacio Guerrero-Ros, Ph.D., or David Schull

Russo Partners, LLC

[ignacio.guerrero-ros@russopartnersllc.com](mailto:ignacio.guerrero-ros@russopartnersllc.com)

[David.schull@russopartnersllc.com](mailto:David.schull@russopartnersllc.com)

(858) 717-2310

### **Investor Contact**

Kevin Gardner

LifeSci Advisors

[kgardner@lifesciadvisors.com](mailto:kgardner@lifesciadvisors.com)

617-283-2856

clene-logo-2x.png

Source: Clene Inc.